Dr. Saadah Alrajab, MD

Dr. Alrajab practices at Saadah Alrajab MD MPH Inc in Yorba Linda, California.

Dr. Alrajab's NPI, 1023050135, was assigned on June 12, 2006. Dr. Alrajab graduated from University of Aleppo Faculty of Medicine in 2000. Dr. Alrajab holds California license A89139.

Dr. Alrajab's primary practice is Saadah Alrajab MD MPH Inc, at 21520 Yorba Linda Blvd, Yorba Linda, CA 92887 in Orange County. The practice phone is (714) 481-0172.

Dr. Alrajab's primary practice is Saadah Alrajab MD MPH Inc in Yorba Linda, California. Dr. Alrajab is also affiliated with Providence St. Jude Medical Center. The medical group on file is Orange County Lung Center. Dmand AI also links Dr. Alrajab to 6 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alrajab practices, 8 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Alrajab's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Alrajab is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Alrajab's licenses on file in 2 states: California and Louisiana.

CMS data shows 7,310 Medicare services from Dr. Alrajab across 15 procedure codes in 2024, for 722 Medicare patients. Medicare paid $548,535 for them.

CMS counts 722 Medicare patients who saw Dr. Alrajab in 2024. The largest group is 65 to 74, with 237 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 74% are also on Medicaid. Their average risk score is 3.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alrajab's median patient age at 70, with 46% women.

In 2024, Dr. Alrajab wrote 368 Medicare Part D claims for 63 patients. 46% of them were for generic drugs. CMS names the drug for 247 of them, across 10 drugs with 11 or more claims each, at $496,169 in total drug cost. In 2023, CMS named 182 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Alrajab for performance year 2024, reported individually. Dr. Alrajab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alrajab as offering telehealth.

Dmand AI links 17 papers to Dr. Alrajab, published from 2011 to 2016. 2011 was the busiest year, with 2. The most frequent topics are Pneumothorax, Ultrasonography and Radiography. Dr. Alrajab has published most often in Chest. Dr. Alrajab's most frequent co-authors are Askin Uysal, MD, Firas Abubaker, MD and John Paul Areno, MD.

CMS Open Payments shows 14 general payments to Dr. Alrajab from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $78.

Dmand AI lists 2 awards for Dr. Alrajab, most recently doctor choice in 2016.

Dr. Alrajab graduated from University of Aleppo Faculty of Medicine in 2000. Dr. Alrajab is a member of ACCP.

Dr. Alrajab is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.